Emily Culbert
Obstetrics Las Vegas, NV Medical Doctor
NPI 1528181625 CMS profile 862068
6355 S Buffalo Dr Fl 3, Las Vegas, NV 89113
General payments
$850
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Emily Culbert of Las Vegas, NV is reported in the CMS Open Payments database as having received $850 across 48 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 56th percentile of Obstetrics profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $125 | 6 | |
| 2024 | General | $107 | 4 | |
| 2023 | General | $157 | 7 | |
| 2022 | General | $132 | 11 | |
| 2021 | General | $84 | 5 | |
| 2020 | General | $91 | 6 | |
| 2019 | General | $153 | 9 |
Beside peers
- Emily Culbert
- Obstetrics median
- Middle half of Obstetrics
- National median
In program year 2025, general payments to Emily Culbert were reported at $125. Among 649 Obstetrics profiles paid that year, the median was $181 and the middle half received between $61 and $424.
Show as a table
| Year | Emily Culbert | Obstetrics median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $153 | $177 | $60–$381 | $163 |
| 2020 | $91 | $92 | $35–$201 | $114 |
| 2021 | $84 | $125 | $40–$351 | $132 |
| 2022 | $132 | $186 | $65–$448 | $149 |
| 2023 | $157 | $183 | $61–$451 | $160 |
| 2024 | $107 | $176 | $62–$406 | $164 |
| 2025 | $125 | $181 | $61–$424 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 11 drugsPart D claims
325
Drug cost
$23,368
Branded share of claims
37.2%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Premarin Estrogens, Conjugated | Brand | 20 | $7,104 | |
| Estradiol | Generic | 89 | $5,851 | |
| Estradiol (Twice Weekly) Estradiol | Brand | 44 | $5,826 | |
| Progesterone Progesterone, Micronized | Brand | 38 | $1,581 | |
| Clobetasol Propionate | Generic | 37 | $898 | |
| Valacyclovir Valacyclovir Hcl | Brand | 19 | $807 | |
| Alendronate Sodium | Generic | 24 | $493 | |
| Metronidazole | Generic | 13 | $257 | |
| Acyclovir | Generic | 12 | $221 | |
| Solifenacin Succinate | Generic | 12 | $216 |
The 10 drugs with the highest cost, of 11 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 24,311 Part D prescribers listed as Obstetrics & Gynecology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 24 billing codesPaid by Medicare
$4,131
Medicare patients
31
Services billed
103
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 45% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
48 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Obstetrics in Nevada
Related records
Obstetrics in Nevada
Practitioners in the same specialty and state, ranked by reported value.
All Obstetrics
Everyone recorded under this specialty, nationwide.
Doctors in Nevada
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.